STOCK TITAN
  1. Home
  2. Sec-filings
  3. KROS
  4. [Form 4] Keros Therapeutics, Inc. Insider Trading Activity

Keros Therapeutics (KROS) director Newton sells 550 shares in planned trade

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Keros Therapeutics director Charles W. Newton reported an open-market sale of 550 shares of common stock at a weighted average price of $10.04 per share. The transaction occurred on June 11, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026. After this sale, Newton directly holds 12,665 shares of Keros Therapeutics common stock.

Positive

  • None.

Negative

  • None.
Insider Newton Charles W.
Role null
Sold 550 shs ($6K)
Type Security Shares Price Value
Sale Common Stock 550 $10.04 $6K
Holdings After Transaction: Common Stock — 12,665 shares (Direct, null)
Footnotes (1)
  1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.83 to $10.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Shares sold 550 shares Open-market sale on June 11, 2026
Average sale price $10.04 per share Weighted average sale price for 550 shares
Post-transaction holdings 12,665 shares Shares directly held after June 11, 2026 sale
Price range $9.83–$10.16 per share Range of prices for multiple sale executions
Rule 10b5-1 trading plan financial
"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Newton Charles W.
(Last)(First)(Middle)
C/O KEROS THERAPEUTICS, INC.
1050 WALTHAM STREET, SUITE 302
(Street)
LEXINGTON MASSACHUSETTS 02421
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/11/2026S(1)550D$10.04(2)12,665D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.83 to $10.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Esther Cho, Attorney-in-Fact06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Keros Therapeutics (KROS) disclose for Charles W. Newton?

Keros Therapeutics disclosed that director Charles W. Newton sold 550 shares of common stock in an open-market transaction at a weighted average price of $10.04 per share. Following this sale, he directly holds 12,665 Keros Therapeutics shares.

When did the latest Keros Therapeutics (KROS) insider sale by Charles W. Newton occur?

The reported insider sale by Keros Therapeutics director Charles W. Newton occurred on June 11, 2026. He sold 550 common shares in an open-market transaction at a weighted average price of $10.04 per share under a pre-arranged trading plan.

How many Keros Therapeutics (KROS) shares does Charles W. Newton hold after the reported sale?

After the reported sale, Keros Therapeutics director Charles W. Newton directly holds 12,665 shares of common stock. This figure reflects his remaining position following the open-market disposition of 550 shares on June 11, 2026.

Was the Keros Therapeutics (KROS) insider sale by Charles W. Newton under a Rule 10b5-1 plan?

Yes. The filing states that Charles W. Newton’s sale of 550 Keros Therapeutics shares was conducted pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026. Such plans pre-schedule trades, reducing discretion over transaction timing.

At what prices were Charles W. Newton’s Keros Therapeutics (KROS) shares sold?

The filing reports a weighted average sale price of $10.04 per share for Charles W. Newton’s 550 Keros Therapeutics shares. Footnotes indicate individual trades occurred between $9.83 and $10.16 per share in multiple transactions.